Chemomab Therapeutics LTD 20-F annual reports
The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.
NASDAQ
Chemomab Therapeutics Ltd. reported significant losses and a going concern warning, even as its lead drug nebokitug showed positive Phase 2 results for Primary Sclerosing Cholangitis and advanced to Phase 3 planning.
NASDAQ
20-F: Chemomab Therapeutics Reports Positive Data, Aligns with FDA on Phase 3 Trial for PSC Treatment
Chemomab Therapeutics announces positive clinical data from its PSC SPRING study and alignment with the FDA on a Phase 3 registration study for nebokitug, a potential treatment for Primary Sclerosing Cholangitis.
NASDAQ
20-F: Chemomab Therapeutics Ltd. Files 20-F Annual Report, Outlines Financials and Clinical Progress
Chemomab Therapeutics Ltd. releases its 20-F filing, detailing financial results, clinical trial updates, and future strategies for its lead product candidate, CM-101.